Latest news
Annexon, Inc. Reports Early Clinical Responses in First U.S. and European Patient Cohort of GBS FORWARD Study with Tanruprubart - marketscreener.commarketscreener.com · Thu, 06 Aug 2026 15:47:18 GMTAnnexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week - Yahoo FinanceYahoo Finance · Thu, 06 Aug 2026 12:00:00 GMT